These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29396246)

  • 1. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
    Kahaly GJ; Riedl M; König J; Pitz S; Ponto K; Diana T; Kampmann E; Kolbe E; Eckstein A; Moeller LC; Führer D; Salvi M; Curro N; Campi I; Covelli D; Leo M; Marinò M; Menconi F; Marcocci C; Bartalena L; Perros P; Wiersinga WM;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):287-298. PubMed ID: 29396246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial.
    Lanzolla G; Sabini E; Leo M; Menconi F; Rocchi R; Sframeli A; Piaggi P; Nardi M; Marcocci C; Marinò M
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):733-742. PubMed ID: 34592164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
    Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
    Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic safety analysis of mycophenolate in Graves' orbitopathy.
    Lee ACH; Riedl M; Frommer L; Diana T; Kahaly GJ
    J Endocrinol Invest; 2020 Jun; 43(6):767-777. PubMed ID: 31834613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
    Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
    Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
    Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
    Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
    Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study.
    Ng CM; Yuen HK; Choi KL; Chan MK; Yuen KT; Ng YW; Tiu SC
    Hong Kong Med J; 2005 Oct; 11(5):322-30. PubMed ID: 16219950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
    Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
    Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
    [No Abstract]   [Full Text] [Related]  

  • 16. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
    Pramono LA
    Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy.
    Riedl M; Kuhn A; Krämer I; Kolbe E; Kahaly GJ
    J Endocrinol Invest; 2016 Jun; 39(6):687-94. PubMed ID: 26886940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy.
    Ye X; Bo X; Hu X; Cui H; Lu B; Shao J; Wang J
    Clin Endocrinol (Oxf); 2017 Feb; 86(2):247-255. PubMed ID: 27484048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
    Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
    Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study on the use of prednisolone-encapsulated liposomes for the treatment of moderate-to-severe Graves' orbitopathy with reduced systemic steroid exposure.
    Detiger SE; Kremer TM; A S H Dalm V; de Keizer ROB; Wubbels RJ; Metselaar JM; van Hagen PM; Peeters RP; Paridaens D
    Acta Ophthalmol; 2021 Nov; 99(7):797-804. PubMed ID: 33423386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.